FDA Expedites Review for Endometrial Cancer Drug

The FDA has granted priority review to sacituzumab tirumotecan (sac-TMT), an investigational treatment for adults with pretreated endometrial cancer. This decision follows positive Phase 3 trial data indicating a significant reduction in the risk of death and disease progression. Priority review could accelerate the availability of this new therapeutic option for patients with limited treatment alternatives.